1. Home
  2. AIRI vs XCUR Comparison

AIRI vs XCUR Comparison

Compare AIRI & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$2.58

Market Cap

12.3M

Sector

Industrials

ML Signal

HOLD

XCUR

Exicure Inc.

N/A

Current Price

$1.12

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRI
XCUR
Founded
1979
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
13.7M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
AIRI
XCUR
Price
$2.58
$1.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.0K
40.1K
Earning Date
05-14-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
24.39
83.37
EPS
N/A
N/A
Revenue
$47,921,000.00
N/A
Revenue This Year
$6.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$1.05
52 Week High
$3.95
$9.48

Technical Indicators

Market Signals
Indicator
AIRI
XCUR
Relative Strength Index (RSI) 42.13 N/A
Support Level N/A N/A
Resistance Level $2.79 N/A
Average True Range (ATR) 0.09 0.00
MACD -0.01 0.00
Stochastic Oscillator 47.37 0.00

Price Performance

Historical Comparison
AIRI
XCUR

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: